State of the Union: A Targeted Approach in First-Line Treatment of CLL/SLL

State of the Union: A Targeted Approach in First-Line Treatment of CLL/SLL

State of the Union: A Targeted Approach in First-Line Treatment of CLL/SLL
RestartResume

How confidently do you select first-line therapy for patients with CLL? Should you use a targeted approach or not? If you do, which one and why?

Available credits: 0.25

Time to complete: 15 minutes

Released:

Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    The process of matching the most optimal first-line therapy to patients with CLL has recently undergone a paradigm shift. Along with a widening focus on targeted agents, untangling key patient- and disease-centric parameters adds complexity to this shared decision. Join Drs. Susan O’Brien and Timothy Call as they offer clarity to this first-line decision process—a clarity that you can readily take into the clinic. 

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Faculty:
    Timothy Call, MD
    Professor of Medicine, Mayo Medical School
    Oncologist, Mayo Clinic
    Rochester, MN

    No relevant relationships reported

    Susan O’Brien, MD
    Associate Director for Clinical Services, Chao Family Comprehensive Cancer Center
    University of California Irvine Medical Center
    Orange, CA

    Research: Acerta Pharma, Alliance Pharma, Beigene, Caribou Biosciences, Gilead Sciences, Inc., Loxo Oncology, MustangBio, Nurix, Pfizer, Pharmacyclics, Regeneron, TG Therapeutics
    Consulting Fees: AbbVie, Alexion, Amgen, Aptose Biosciences Inc., Astellas, AstraZeneca, Autolus, Bristol Myers Squibb, Celgene, DynaMed, Eli Lilly and Company, Gilead Sciences, Inc., GlaxoSmithKline, Janssen Oncology, Johnson & Johnson, Juno Pharmaceuticals, Lumina Corps (formerly NOVA Research Company), MEI Pharma, Merck & Co., Inc., Pfizer, Pharmacyclics, TG Therapeutics, Vaniam Group LLC, Verastem Oncology, Vida Ventures

    Reviewers/Content Planners/Authors:

    • Jorge Bacigalupo has nothing to disclose.
    • Stephen Chavez has nothing to disclose.
    • Cindy Davidson has nothing to disclose.
    • Barry Fiedel, PhD, has nothing to disclose.
    • Colleen Resnick has nothing to disclose. 
    • Terra Sumstine has nothing to disclose.
    • Anna Trentini has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    1. Select therapy for patients with treatment-naïve chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) based on patient-, disease-, and treatment-related factors
    2. Apply efficacy and safety data from clinical trial results to the selection of initial therapy for patients with CLL or SLL
  • Target Audience

    This activity is designed to meet the educational needs of community oncologists, hematologist-oncologists, and medical oncologists. 

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for .25 contact nursing hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for .25 AAPA Category 1 CME credits. Approval is valid until June 30, 2023. PAs should claim only the credit commensurate with the extent of their participation in the activity. 

  • Provider(s)/Educational Partner(s)

    Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 
    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research.  

  • Commercial Support

    This activity is supported by independent educational grants from AbbVie and Janssen Scientific Affairs, LLC.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

5-Year Follow-Up Update of the MAIA Study
Charles Turck, PharmD, BCPS, BCCCP

NEW FEATURES:

Register

We’re glad to see you’re enjoying Global Oncology Academy…
but how about a more personalized experience?

Register for free